[{"address1": "500 Unicorn Park Drive", "address2": "Suite 303", "city": "Woburn", "state": "MA", "zip": "01801", "country": "United States", "phone": "781 222 9600", "website": "https://www.replimune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.", "fullTimeEmployees": 331, "auditRisk": 8, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 7.87, "open": 7.9, "dayLow": 7.87, "dayHigh": 8.86, "regularMarketPreviousClose": 7.87, "regularMarketOpen": 7.9, "regularMarketDayLow": 7.87, "regularMarketDayHigh": 8.86, "beta": 1.157, "forwardPE": -3.1598513, "volume": 9777100, "regularMarketVolume": 9777100, "averageVolume": 1213643, "averageVolume10days": 2829750, "averageDailyVolume10Day": 2829750, "bid": 8.45, "ask": 8.5, "bidSize": 200, "askSize": 400, "marketCap": 522028352, "fiftyTwoWeekLow": 4.92, "fiftyTwoWeekHigh": 24.28, "fiftyDayAverage": 6.7459, "twoHundredDayAverage": 9.738125, "currency": "USD", "enterpriseValue": 177229392, "floatShares": 39120194, "sharesOutstanding": 61415100, "sharesShort": 8693465, "sharesShortPriorMonth": 8341398, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1416, "heldPercentInsiders": 0.05185, "heldPercentInstitutions": 1.00634, "shortRatio": 12.55, "shortPercentOfFloat": 0.16139999, "impliedSharesOutstanding": 65779400, "bookValue": 6.098, "priceToBook": 1.3938997, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -215794000, "trailingEps": -3.24, "forwardEps": -2.69, "enterpriseToEbitda": -0.77, "52WeekChange": -0.6364414, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "REPL", "underlyingSymbol": "REPL", "shortName": "Replimune Group, Inc.", "longName": "Replimune Group, Inc.", "firstTradeDateEpochUtc": 1532093400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ea19e92f-8d00-3fa8-9834-419bd79af5bf", "messageBoardId": "finmb_571664452", "gmtOffSetMilliseconds": -14400000, "currentPrice": 8.5, "targetHighPrice": 17.0, "targetLowPrice": 10.0, "targetMeanPrice": 14.0, "targetMedianPrice": 13.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 420668000, "totalCashPerShare": 6.85, "ebitda": -230198000, "totalDebt": 75869000, "quickRatio": 10.525, "currentRatio": 10.724, "debtToEquity": 20.258, "returnOnAssets": -0.2566, "returnOnEquity": -0.46417, "freeCashflow": -115868624, "operatingCashflow": -185467008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]